Wight R G, Jones A S, Beckingham E, Andersson B, Ek L
St Marys Hospital, Paddington, London, UK.
Clin Otolaryngol Allied Sci. 1992 Aug;17(4):354-8. doi: 10.1111/j.1365-2273.1992.tb01012.x.
A randomized double blind placebo controlled cross-over study comparing budesonide 400 micrograms and budesonide 800 micrograms daily in 59 patients is presented. Nasal obstruction was the predominant symptom and was subjectively and objectively improved by both doses of budesonide (P less than 0.001). No significant difference was found between the two treatments. Both patient subgroups with non-allergic, non-eosinophilic rhinitis and perennial allergic rhinitis benefitted from therapy. Basal and stimulated plasma cortisol levels remained unchanged with either dose of budesonide, and no increase in adverse effects occurred with higher dose therapy.
本文介绍了一项随机双盲安慰剂对照交叉研究，该研究对59例患者每日使用400微克布地奈德和800微克布地奈德进行了比较。鼻塞是主要症状，两种剂量的布地奈德均在主观和客观上改善了鼻塞症状（P<0.001）。两种治疗方法之间未发现显著差异。非过敏性、非嗜酸性鼻炎和常年性过敏性鼻炎这两个患者亚组均从治疗中获益。两种剂量的布地奈德治疗后，基础和刺激后的血浆皮质醇水平均保持不变，高剂量治疗未增加不良反应的发生率。
